

ANTI-ATHEROSCLEROTIC AND
HEPATOPROTECTIVE EFFECTS OF TRIHONEY IN
HYPERCHOLESTEROLEMIC RABBITS

BY

HAMAD ABDULSALAM HAMAD ALFARISI

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Health Sciences

Kulliyyah of Allied Health Sciences
International Islamic University Malaysia

SEPTEMBER 2020

ABSTRACT

Cardiovascular diseases are major contributor to morbidity and mortality worldwide. Atherosclerosis is a leading cause to cardiovascular diseases in addition to its pathogenic association with non-alcoholic fatty liver disease (NAFLD). Protection against atherosclerosis and NAFLD constitutes a global aim. Modern trend has emerged to reintroduce natural products such as honey for management of these metabolic epidemics because of the less side effects perhaps. In the present study, Trihoney was investigated for its anti-atherosclerotic and hepatoprotective effects in diet induced hypercholesterolemic rabbits model. Forty-eight male New Zealand white rabbits were randomly assigned to one of 6 groups. First group was fed only commercial rabbit diet, second group was fed commercial rabbit diet with 0.6g of Trihoney/kg/day, third group was fed 1% cholesterol diet, fourth and fifth groups were fed 1% cholesterol diet with 0.3 and 0.6 g of Trihoney/kg/day while the last group was fed 1% cholesterol diet plus 2mg of atorvastatin/kg/day. Experiment continues for 12 weeks duration. Blood samples were withdrawn before and after the experimental period. Aorta and liver were harvested and processed for homogenate and histopathological studies. In the first phase, Trihoney was investigated for its lipid lowering and anti-inflammatory effects through analysis of serum lipids [total cholesterol (TC), low-density lipoprotein (LDL-c), high-density lipoprotein (HDL-c), triglycerides (TG) and TC/HDL risk ratio] and by assay of serum pro-atherogenic inflammatory cytokines [interleukin-1 β (IL-1 β), interleukin-6 (IL-6) and tumour necrosis factor- α (TNF- α)]. The results showed that Trihoney had significant lipid lowering and marked anti-inflammatory effects. In the second phase, Trihoney was assessed for antioxidant function by analysing serum and aorta homogenate for superoxide dismutase (SOD), glutathione peroxidase (GPx) and malondialdehyde (MDA), in addition to analysing serum for oxidised-LDL (Ox-LDL). Results showed that Trihoney exerted significant antioxidant effects systemically as well as locally in the aorta. In the third phase, Trihoney was investigated of its effects on the atherosclerotic plaques, inflammatory adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and on homocysteine. Results showed that Trihoney had significant anti-inflammatory and vascular protective functions. In the fourth phase, Trihoney was examined for hepatoprotective function against NAFLD through histopathological study and *via* assay of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (T. Bil.), alkaline phosphatase (ALP), fasting glucose, fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR). In addition to antioxidant assay of liver homogenate for SOD, GPx and MDA. Results showed that under status of sustained hypercholesterolemia, Trihoney was able to normalise hepatic function in NAFLD induced hypercholesterolemia, Trihoney showed no effect on fasting glucose, insulin and HOMA-IR, Trihoney exhibited significant antioxidant effect against hepatic oxidative stress and it was protective against progression of NAFLD to non-alcoholic steatohepatitis (NASH). Accordingly, Trihoney has a potential protective role against atherosclerosis and NAFLD through hypocholesterolemic, antioxidant and anti-inflammatory functions. Further studies may be needed to explore possible molecular mechanisms underlying those health beneficial properties of Trihoney.

خلاصة البحث

تعتبر أمراض القلب والأوعية الدموية المساهم الرئيسي في الوفيات على مستوى العالم. ويعد تصلب الشرايين (Atherosclerosis) سببا مباشرا لأمراض القلب والأوعية الدموية بالإضافة الى ارتباطه بالمرض بمرض الكبد الدهني غير الكحولي (NAFLD). حديثا أعتبر العمل على الوقاية من مرض تصلب الشرايين ومرض الكبد الدهني غير الكحولي هدفا عالميا. هناك ظهور لتوجه حديث لإعادة المنتجات الطبيعية مثل العسل واستخدامها في علاج هذه الأوبئة الأيضية. في هذه الدراسة تم التحقق من الأثر الوقائي للعسل الثلاثي ضد مرض تصلب الشرايين ومرض الكبد الدهني غير الكحولي باستخدام نموذج غذائي مفرط الكوليستيرول في الأرانب النيوزيلاندية البيضاء. تم توزيع 48 أرنا ذكرا الى 6 مجموعات. تم تغذية المجموعة الأولى بالغذاء التجاري للأرانب والمجموعة الثانية بالغذاء التجاري للأرانب بالإضافة الى جرعة يومية من العسل الثلاثي بمقدار 0.6 جم/كجم/يوم. أما المجموعة الثالثة فتم تغذيتها فقط بالغذاء المرتفع الكوليستيرول والمجموعتين الرابعة و الخامسة تم تغذيتهاما بالغذاء مرتفع الكوليستيرول بالإضافة الى جرعة يومية من العسل بمقدار 0.3 و 0.6 جم/كجم/يوم على التوالي. أما المجموعة السادسة تم تغذيتها بالغذاء المرتفع الكوليستيرول بالإضافة الى جرعة يومية من دواء الأتورفاستاتين المخفض للدهون بمقدار 2 ملجم/كجم/يوم. استمرت التجربة لمدة 12 أسبوعا. تم اختبار معدل الدهون و وظائف الكبد والأنزيمات المضادة للأكسدة وكذلك تم اختبار المؤشرات الالتهابية الدالة على تصلب الشرايين في مصلى الدم. وتمت دراسة مضادات الأكسدة في كل من نسيجي الشريان الأورطي والكبد وتم أيضا اجراء دراسة نسيجية على كل من الشريان الأورطي والكبد باستخدام تقنيات متعددة لصبغ الأنسجة. أظهرت النتائج التأثير الوقائي للعسل الثلاثي ضد مرض تصلب الشرايين وضد مرض الكبد الدهني غير الكحولي عن طريق خفض معدل الدهون والحفاظ على وظائف الكبد في معدلها الطبيعي بالإضافة الى الدور الوقائي المضاد للأكسدة وخفض مؤشرات التهاب تصلب الشرايين. كما أظهر العسل الثلاثي دورا وقائيا على مستوى خفض لويحات تصلب الشرايين والتركيب النسيجي للكبد. بناء على ذلك فإن للعسل الثلاثي دورا وقائيا ضد تصلب الشرايين ومرض الكبد الدهني غير الكحولي من خلال خفض معدل الدهون و الالتهابات. بالإضافة إلى قدرة العسل الثلاثي على إخماد الأكسدة المصاحبة لهذه الأمراض. قد تكون هناك حاجة الى دراسات مستقبلية لأستكشاف اليات عمل العسل الثلاثي على المستوي الجزيئي و الجيني.

APPROVAL PAGE

The thesis of Hamad Abdulsalam Hamad Alfarisi has been approved by the
following:

Muhammad Bin Ibrahim
Supervisor

Asmah Hanim Bt. Hamdan
Co-Supervisor

Radiah Bt. Abdul Ghani
Internal Examiner

Hamid Jan B. Jan Mohamed
External Examiner

Kamarul Ariffin Khalid
Chairman

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Hamad Abdulsalam Hamad Alfarisi

Signature.....

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**ANTI-ATHEROSCLEROTIC AND HEPATOPROTECTIVE
EFFECTS OF TRIHONEY IN HYPERCHOLESTEROLEMIC
RABBITS**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2020 by Hamad Abdulsalam Hamad Alfarisi and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Hamad Abdulsalam Hamad Alfarisi

.....
Signature

.....
Date

ACKNOWLEDGEMENTS

In the name of Allah, the Entirely Merciful, Especially Merciful. And may His peace and blessings be upon our Prophet Muhammad the Messenger of Allah. Foremost I thank Allah for helping me to complete this work as a requirement for the degree of Doctor of Philosophy in Health Sciences-Nutrition Sciences.

To my parents I would like to express my warmest gratitude, and immeasurable love and appreciation, all the support they have provided me over the years was the greatest gift anyone has ever given me, they pray for me with each heartbeat, with each sunrise and sunset, I dedicated this work.

I would like to express my deepest gratitude to my supervisor Assoc. Prof. Dr. Muhammad Bin Ibrahim for his guidance, encouragement, patience, indispensable advice, information and support, throughout this project. I pray that Allah support and bless you and your highly respected family.

I would like to extend my thanks to my co supervisors Asst. Prof. Dr. Asmah Hanim and Asst. Prof. Dr. Che Anuar Che Mohamad for their advice and for their support during my laboratory work.

To my family, I would like to stand with a great love and appreciation, my family provided me the help, the support and the motivation. This journey would not have been possible without the support of my wife Zenab Bubaker Hamad, thank you my beloved wife for encouraging, and supporting me. To my sons, Hothaifa and Mohammed you are the gift that Allah gave me, you are the spirit by which I am living, may Allah bless and protect you.

I would also like to express my sincere gratitude to Libyan Programme for Reintegration and Development and to Libyan Ministry of Higher Education who sponsor me during my stay in Malaysia.

I am also thankful to the entire staff of Kulliyah of Allied Health Sciences, Central Research and Animal Facility (CREAM, IIUM Kuantan), Department of Basic Medical Sciences at Kulliyah of Pharmacy and Histopathology and Laboratory Medicine at IIUM Medical Centre for providing facilities and suitable working environment during my research.

Finally, the best thing I would like to say is “Alhamdu liLLAHI Rabbil A’lamiin”.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval Page.....	iv
Declaration.....	v
Copyright Page.....	vi
Acknowledgements.....	vii
Table of contents.....	viii
List of Tables	xvi
List of Figures	xviii
List of Abbreviations	xxi
List of Symbols	xxiv
CHAPTER ONE: INTRODUCTION	1
1.1 Background of the Study	1
1.2 Statement of Research Problem and Significance of the Study	3
1.3 Research Objectives	5
1.3.1 General Objective	5
1.3.2 Specific Objectives	6
1.3.3 Research Questions	6
1.3.4 Hypothesis.....	7
CHAPTER TWO: LITERATURE REVIEW.....	8
2.1 Noncommunicable Diseases.....	8
2.2 Cardiovascular Diseases (CVD).....	9
2.2.1 Epidemiology and Global Burden of Cardiovascular Diseases	9
2.2.2 Economic Burden of Cardiovascular Diseases	12
2.2.3 Cardiovascular Diseases in Malaysia.....	13
2.2.4 Risk Factors of Cardiovascular Diseases	15
2.2.4.1 Dyslipidaemia and Hypercholesterolemia.....	16
2.2.4.2 Biochemical Definition of Normal Lipid Profile and Dyslipidaemia	17
2.2.4.3 Physiology of Cholesterol and Lipoproteins	17
2.2.4.4 Blood Cholesterol and Lipoproteins in Cardiovascular Risk Assessment	18
2.2.5 Prevention of Cardiovascular Diseases.....	20
2.2.6 Treatment of Cardiovascular Diseases.....	21
2.2.6.1 Lipid Lowering Drugs	22
2.3 Atherosclerosis	23
2.3.1 Definition of Atherosclerosis	23
2.3.2 Atherosclerosis Risk Factors.....	24
2.3.2.1 Low Density Lipoprotein Cholesterol (LDL-c) and Small Dense Low-Density Lipoprotein (sdLDL)	24
2.3.2.2 Novel Atherosclerotic Risk Biomarkers and Their Clinical Significance	25
2.3.2.2.1 Homocysteine	26

2.3.2.2.2 High-Sensitivity C-reactive Protein (hs-CRP).....	27
2.3.2.2.3 Triglycerides (TG)	28
2.3.3 Inflammatory Biomarkers of Atherosclerosis.....	28
2.3.3.1 Inflammatory Cytokines	29
2.3.3.2 Tumour Necrosis Factor- α (TNF- α).....	29
2.3.3.3 Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1).....	30
2.3.4 Pathogenesis of Atherosclerosis	32
2.3.4.1 Development of Atherosclerotic Fatty Streaks.....	33
2.3.4.1.1 Trapping and Oxidation of Low Density Lipoprotein Cholesterol (LDL-c).....	34
2.3.4.1.2 The Pathological Hallmark of Fatty Streaks Development	35
2.3.4.2 Inflammatory and Immune Mechanisms Induced by Oxidized LDL-c	35
2.3.4.3 Atherosclerotic Lesion Progression Induced by Oxidized LDL-c in Conjunction with Inflammatory Role of Macrophages	36
2.3.4.4 Role of Oxidative Stress in the Pathogenesis of Atherosclerosis.....	37
2.3.4.4.1 Oxidized LDL-C Induces Oxidative Stress	38
2.3.4.4.2 Mechanisms of Oxidative Stress in Atherosclerosis.....	38
2.3.4.5 Role of Diet and Intestinal Flora in the Pathogenesis of Atherosclerosis.....	39
2.3.5 Complications and Clinical Consequences of Atherosclerosis.....	40
2.3.6 Therapeutic Approaches for Atherosclerosis.....	42
2.3.6.1 Drugs for Management of Atherosclerosis.....	43
2.3.6.2 On the Horizon Anti-Atherosclerotic Drugs	45
2.3.6.3 Role of Diet in Protection Against Atherosclerosis	47
2.3.6.4 Dietary Patterns Protective Against Atherosclerosis.....	49
2.4 Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherosclerosis	50
2.4.1 Liver and Lipid Metabolism	50
2.4.2 Hepatic Cholesterol Metabolism.....	51
2.4.3 Liver X Receptors (LXR)	52
2.4.4 Role of Liver X Receptors in Atherosclerosis	52
2.4.5 Non-Alcoholic Fatty Liver Disease (NAFLD)	53
2.4.5.1 Histological Grading and Staging of Non-Alcoholic Steatohepatitis	54
2.4.6 Mechanisms of Non-Alcoholic Fatty Liver Disease.....	56
2.4.7 Links Between Non-Alcoholic Fatty Liver Disease and Atherosclerosis	57
2.4.8 Possible Mechanisms Linking Atherosclerosis with Non- Alcoholic Fatty Liver Disease	58
2.4.8.1 Dyslipidaemia.....	58
2.4.8.2 Insulin Resistance	59
2.4.8.3 Oxidative Stress.....	59
2.4.8.4 Inflammation	59
2.4.8.5 Adipokines.....	60

2.4.9 Treatment of Non-Alcoholic Fatty Liver Disease	61
2.4.9.1 Medical Treatment of Non-Alcoholic Fatty Liver Disease	61
2.4.9.2 Dietary Management of Non-Alcoholic Fatty Liver Disease	61
2.5 Honey.....	62
2.5.1 Composition and Quality of Honey	63
2.5.2 Honey in Islamic Perspectives	67
2.5.3 Bee Taxonomy	68
2.5.4 Mellifera Honey	69
2.5.5 Dorsata Honey	69
2.5.6 Trigona Honey	70
2.5.7 Honey Can Modulate Cardiovascular Risk Factors.....	71
2.5.8 Honey as Hepatoprotective Natural Product.....	73
2.5.9 Honey as A natural Antioxidant	74
2.5.10 Therapeutic Benefits of Honey	75
2.5.10.1 Honey as Anti-Inflammatory Agent.....	75
2.5.10.2 Honey in Wound Healing.....	76
2.5.10.3 Honey as Anti-Microbial Agent	77
2.5.10.4 Honey and Diseases of Gastrointestinal Tract (GIT)	79
2.5.10.5 Some Other Medical Applications of Honey	79
2.5.11 Trihoney.....	81
2.6 Research Animal Models of Hypercholesterolemia and Atherosclerosis	82
2.6.1 Rabbits as A model of Hypercholesterolemia and Atherosclerosis	83
CHAPTER THREE: METHODOLOGY	86
3.1 Materials	86
3.1.1 Equipment	86
3.1.2 Chemicals, Reagents, Assay Kits and Supplements	87
3.2 Methods	89
3.2.1 Sample Size Calculation	89
3.2.2 Ethical Approval	89
3.2.3 Dosage of Trihoney.....	90
3.2.4 Preparation of 1% Cholesterol Diet	91
3.2.5 Preparation of Atorvastatin for Oral Gavage.....	94
3.2.6 Animal, Diet, Treatment and Sacrificing Procedures	94
3.2.7 Blood Collection and Serum Separation.....	100
3.2.8 Organ Harvesting	100
3.2.8.1 Aorta Harvesting	100
3.2.8.2 Liver Harvesting.....	101
3.2.9 Preparation of Aortic and Liver Tissue Homogenates.....	102
3.2.10 Protein Assay of Tissue Homogenates	103
3.2.11 Enzyme Linked Immunosorbent Assay (ELISA) for Serum and Tissue Homogenate	104
3.2.11.1 Serum Lipid Peroxidation (Malondialdehyde-MDA)	104
3.2.11.2 Tissue Homogenates Lipid Peroxidation (Malondialdehyde-MDA) Assay	105

3.2.12 Histopathology Study of Aorta	106
3.2.12.1 Histopathological Study with Haematoxylin and Eosin (H&E) Stain	106
3.2.12.1.1 Aorta Fixation	106
3.2.12.1.2 Grossing	106
3.2.12.1.3 Tissue Processing	106
3.2.12.1.4 Tissue Embedding	107
3.2.12.1.5 Trimming and Sectioning	107
3.2.12.1.6 Haematoxylin and Eosin (H&E) Staining of Aorta	107
3.2.12.1.7 Deparaffinisation	108
3.2.12.1.8 Hydration	108
3.2.12.1.9 Haematoxylin and Eosin Staining	108
3.2.12.1.10 Dehydration	108
3.2.12.1.11 Mounting	108
3.2.12.1.12 Slide Inspection and Picture Caption	109
3.2.12.2 Histopathological Study with Masson's Trichrome (MT) Stain	109
3.2.12.2.1 Deparaffinisation	109
3.2.12.2.2 Hydration	109
3.2.12.2.3 Masson's Trichrome Staining	109
3.2.12.2.4 Dehydration, Mounting, and Picture Caption	110
3.2.13 Histopathology Study of Liver	110
3.2.13.1 Histopathological Study of Liver Using Haematoxylin & Eosin (H&E) Staining	110
3.2.13.2 Histopathological Study of Liver Using Masson's Trichrome Stain	111
3.2.14 Statistical Analysis	111

CHAPTER FOUR: SERUM LIPID LOWERING EFFECT AND ANTI- INFLAMMATORY POTENTIAL OF TRIHONEY AGAINST THE INFLAMMATORY CYTOKINES IN RABBITS FED HIGH CHOLESTEROL DIET	112
4.1 Introduction	112
4.2 Methodology	113
4.2.1 Body Weight and Food Intake Measurement	113
4.2.2 Serum Lipid Profile Analysis	113
4.2.3 Enzyme Linked Immunosorbent Assay (ELISA) For Serum Pro-Atherogenic Inflammatory Cytokines	113
4.2.3.1 Serum Interleukin-1 β	113
4.2.3.2 Serum Interleukin-6 (IL-6) and Tumour Necrosis Factor-Alpha (TNF- α)	115
4.3 Results	116
4.3.1 Effects of Trihoney and 1% Cholesterol Diet on Animal's Food Intake and Body Weight	116
4.3.2 Effects of Trihoney and 1% Cholesterol Diet on Serum Lipid Profile	118

4.3.3 Effects of Trihoney and 1% Cholesterol Diet on Serum Inflammatory Cytokine: Interleukin-1 β (IL-1 β) and its Correlation with the Lipid Profile	122
4.3.4 Effects of Trihoney and 1% Cholesterol Diet on Serum Inflammatory Cytokine: Interleukin-6 (IL-6).....	124
4.3.5 Effects of Trihoney and 1% Cholesterol Diet on Serum Inflammatory Cytokine: Tumour Necrosis Factor- α (TNF- α) ...	125
4.4 Discussion.....	126
4.4.1 Effects of Trihoney and 1% Cholesterol Diet on Animal's Food Intake and Body Weight.....	126
4.4.2 Effects of Trihoney and 1% Cholesterol Diet on Serum Lipid Profile	128
4.4.3 Effects of Trihoney and 1% Cholesterol Diet on Serum Cytokines: Interleukin-1 β (IL-1 β), Interleukin-6 (IL-6) and Tumour Necrosis Factor-Alpha (TNF- α)	133
4.5 Conclusion.....	137

CHAPTER FIVE: ANTIOXIDANT EFFECTS OF TRIHONEY AGAINST OXIDATIVE STRESS IN THE SERUM AND IN THE VASCULAR WALL OF RABBITS FED HIGH CHOLESTEROL DIET.....139

5.1 Introduction	139
5.2 Methodology.....	140
5.2.1 Serum Preparation.....	140
5.2.2 Preparation of Aortic Tissue Homogenate.....	140
5.2.3 Antioxidant Enzyme Assay for Serum and Aortic Tissue Homogenate.....	141
5.2.3.1 Superoxide Dismutase (SOD) Assay.....	141
5.2.3.2 Glutathione Peroxidase (GPx) Assay	142
5.2.4 Enzyme Linked Immunosorbent Assay (ELISA)	144
5.2.4.1 Serum Oxidised Low-Density Lipoprotein (Ox-LDL).....	144
5.2.4.2 Assay of Lipid Peroxidation (Malondialdehyde-MDA) in Serum and in Aortic Tissue Homogenate	145
5.3 Results	146
5.3.1 Effects of Trihoney and 1% Cholesterol Diet on Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in the Serum.....	146
5.3.2 Effects of Trihoney and 1% Cholesterol Diet on Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in Aorta Homogenate.....	147
5.3.3 Effects of Trihoney and 1% Cholesterol Diet on Serum Level of Oxidised Low-Density Lipoprotein (Ox-LDL) and Correlation with Serum Lipid Profile.....	149
5.3.4 Effects of Trihoney and 1% Cholesterol Diet on Lipid Peroxidation-Malondialdehyde (MDA) in Serum and in Aorta Homogenate	151
5.4 Discussion.....	152
5.4.1 Effect of Trihoney on Activity of Antioxidant Enzymes in the Serum and in Homogenate of Aorta.....	152

5.4.2 Effects of Trihoney on Serum Level of Oxidised Low-Density Lipoprotein (Ox-LDL) and on Lipid Peroxidation	156
5.5 Conclusion	162

CHAPTER SIX: EFFECTS OF TRIHONEY ON ATHEROSCLEROTIC PLAQUES, SERUM INFLAMMATORY ADHESION MOLECULES AND HOMOCYSTEINE IN RABBITS FED HIGH CHOLESTEROL DIET	164
6.1 Introduction	164
6.2 Methodology	165
6.2.1 Gross Examination and Scoring of Fatty Streaks	165
6.2.2 Study with Sudan IV Stain.....	166
6.2.3 Histopathological Study with Haematoxylin and Eosin (H&E) Stain.....	166
6.2.4 Histopathological Study with Verhoeff-van Gieson (VGS) Stain.....	167
6.2.5 Histopathological Study with Masson’s Trichrome (MT) Stain.....	168
6.2.6 Measurement of Tunica Intima, Tunica Media, Atherosclerotic Plaque Thicknesses, and Histopathological Description	168
6.2.7 Enzyme Linked Immunosorbent Assay (ELISA)	168
6.2.7.1 Serum Intercellular Adhesion Molecule-1 (ICAM-1).....	168
6.2.7.2 Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) ..	169
6.2.7.3 Serum Homocysteine.....	170
6.3 Results	171
6.3.1 Effect of Trihoney and 1% Cholesterol Diet on Quantity of Atherosclerotic Lesions and Correlation with the Serum Lipid Profile, Oxidised Low-density Lipoprotein and Interleukin-1 β	171
6.3.2 Effects of Trihoney on Thickness of Tunica Intima and Tunica Intima/Tunica Media Thickness Ratio and Correlation with the Lipid Profile	175
6.3.3 Effects of Trihoney and 1% Cholesterol Diet on the Histology of Aortic Wall.....	182
6.3.3.1 Haematoxylin and Eosin (H&E) Study	182
6.3.3.2 Verhoeff-van Gieson (VGS) and Masson’s Trichrome (MT) Stains Study.....	187
6.3.4 Effects of Trihoney and 1% Cholesterol Diet on Serum Adhesion Molecules	195
6.3.4.1 Effect of Trihoney and 1% Cholesterol Diet on Serum Intercellular Adhesion Molecule-1 (ICAM-1).....	195
6.3.4.2 Effects of Trihoney and 1% Cholesterol Diet on Serum Vascular Cell Adhesion Molecule-1 (VCAM-1).....	196
6.3.5 Effects of Trihoney and 1% Cholesterol Diet on Serum Homocysteine	199
6.4 Discussion.....	200

6.4.1 Effects of Trihoney on Atherosclerotic Lesions and Correlations with Serum Lipid Profile, Oxidised Low-density Lipoprotein and Interleukin-1 β	200
6.4.2 Effects of Trihoney on Thickness of Tunica Intima, Atherosclerotic Plaque and Tunica Intima/Tunica Media Thickness Ratio and Correlation with Lipid Profile	202
6.4.3 Effects of Trihoney on Histopathology of Aorta	204
6.4.4 Effects of Trihoney on Serum Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) and Correlation with Serum Lipid Profile and Aortic Lesions	208
6.4.5 Effect of Trihoney on Serum Homocysteine Level	211
6.5 Conclusion	213

CHAPTER SEVEN: HEPATOPROTECTIVE EFFECTS OF TRIHONEY AGAINST NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN RABBITS FED HIGH CHOLESTEROL DIET- LINK WITH ATHEROSCLEROSIS216

7.1 Introduction	216
7.2 Methodology.....	217
7.2.1 Measurement of Relative Liver Weight.....	218
7.2.2 Histopathological Study.....	218
7.2.2.1 Study with Haematoxylin and Eosin (H&E) Stain.....	218
7.2.2.2 Study with Masson’s Trichrome Stain	218
7.2.3 Analysis of Liver Function Test, Fasting glucose, Fasting Insulin and Calculation of HOMA-IR.....	219
7.2.4 Preparation of Liver Tissue Homogenate	219
7.2.5 Antioxidant study.....	220
7.2.5.1 Serum Superoxide Dismutase (SOD) Assay	220
7.2.5.2 Glutathione Peroxidase (GPx) Assay	220
7.2.5.3 Assay of Lipid Peroxidation (Malondialdehyde-MDA) in Liver Homogenate	220
7.3 Results	221
7.3.1 Effect of Trihoney and 1% Cholesterol Diet on Relative Liver Weight and on Liver Histopathology	221
7.3.1.1 Macroscopic Study and Relative Organ Weight	221
7.3.1.2 Microscopic Histopathological Study with Haematoxylin and Eosin (H&E) and Masson’s Trichrome (MT) Stains	225
7.3.2 Effect of Trihoney and 1% Cholesterol Diet on Liver Function and Correlation with Serum Lipid Profile.....	232
7.3.3 Effect of Trihoney on Insulin Resistance in Established Non-Alcoholic Fatty Liver Disease.....	237
7.3.4 Antioxidant Effects of Trihoney on Established Non-Alcoholic Fatty Liver Disease (NAFLD).....	239
7.3.4.1 Effect of Trihoney on Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in Liver Homogenate of Non-Alcoholic Fatty Liver Disease (NAFLD).....	239

7.3.4.2 Effect of Trihoney on Lipid Peroxidation (Malondialdehyde-MDA) in Liver Homogenate of Non-Alcoholic Fatty Liver Disease (NAFLD)	240
7.4 Discussion.....	241
7.4.1 Effects of Trihoney and 1% Cholesterol Diet on Histopathology of Liver in Non-Alcoholic Fatty Liver Disease.....	241
7.4.2 Effects of Trihoney and 1% Cholesterol Diet on Liver Function in Established Non-Alcoholic Fatty Liver Disease (NAFLD)	245
7.4.3 Effect of Trihoney on Insulin Resistance in Established Non- Alcoholic Fatty Liver Disease (NAFLD).....	249
7.4.4 Effects of Trihoney on Activities of Antioxidant Enzymes, Oxidative Stress and on Lipid Peroxidation in Non- Alcoholic Fatty Liver Disease (NAFLD).....	250
7.4.5 Link Between Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherosclerosis	254
7.5 Conclusion	256
CHAPTER EIGHT: GENERAL DISCUSSION AND RECOMMENDATION	258
8.1 General Discussion	258
8.2 General Conclusion	261
8.3 Postulated Mechanistic Pathway for the Protective Functions of Trihoney Against Atherosclerosis and Non-Alcoholic Fatty Liver Disease.....	263
8.4 Recommendation	264
8.5 Limitation of the Study.....	264
REFERENCES.....	265
APPENDIX I: TRIHONEY	320
APPENDIX II: JOURNAL ARTICLES.....	323
APPENDIX III: ACADEMIC AWARDS/WORKSHOPS	331

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	The Five Major Lipid Modifying Drugs	22
2.2	Histopathological Progression and Characteristics of Atherosclerotic Plaque	41
2.3	Histopathological Classification of Atherosclerotic Plaque According to the American Heart Association (AHA)	42
2.4	Staging and Grading System for Non-Alcoholic Steatohepatitis	55
2.5	Staging System of Fibrosis in Non-Alcoholic Steatohepatitis	55
2.6	Average Composition of Honey	66
2.7	Composition and Some Biochemical Characteristics of Trihoney	82
3.1	Nutrition Information of the Extra Virgin Coconut Oil	93
3.2	Nutritional Composition of the Standard Rabbit Pellet Used in the Animal Experiment (Percentage/25kg), Perternakan Hong Lee Sdn. Bhd	95
3.3	Grouping and Treatment of Animals	96
4.1	Effects of 1% Cholesterol Diet and Trihoney on Animal's Food Intake and Body Weight at Week 0 and Week 12	117
4.2	Baseline, Week 12 and Percentage Change (%) of Serum Total Cholesterol (TC) and Low-Density Lipoprotein (LDL-c)	120
4.3	Baseline, Week 12 and Percentage Change (%) of Serum High-Density Lipoprotein (HDL-c) and Triglycerides (TG)	120
4.4	Effects of 1% Cholesterol Diet and Trihoney on Serum Interleukin-1 β (IL-1 β) at Week 12	123
4.5	Correlation Between Serum Interleukin-1 β (IL-1 β), Serum Total Cholesterol (TC) and Serum Low-Density Lipoprotein Cholesterol (LDL-c)	124
4.6	Effects of 1% Cholesterol Diet and Trihoney On Serum Interleukin-6 (IL-6) at Week 12	125
4.7	Effects of Trihoney and 1% Cholesterol Diet on Serum Tumour Necrosis Factor- α (TNF- α) at Week 12	126

5.1	Correlation (<i>r</i>) Between Serum Oxidised Low-Density Lipoprotein (Ox-LDL) Level and Serum Lipid Profile	151
5.2	Effect of Trihoney and 1% Cholesterol Diet on Malondialdehyde (MDA) Concentration in Serum and in Aortic Homogenate at Week 12	152
6.1	Correlation (<i>r</i>) Between Aortic Lesion Area Percentage, Serum Lipid Profile and Oxidised Low-density Lipoprotein	174
6.2	Correlation Between Aortic Lesion Area Percentage and Serum Interleukin-1 β (IL-1 β) at Week 12	175
6.3	Comparison of Atherosclerotic Plaque Thickness, and Tunica Intima/Tunica Media Thickness Ratio	176
6.4	Correlation (<i>r</i>) Between Atherosclerotic Plaque Thickness, Tunica Intima/Tunica Media Thickness Ratio and Serum Lipid Profile	177
6.5	Correlation Between Serum Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) and Serum Lipid Profile	198
6.6	Correlation Between Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) and Aortic Lesion Area Percentage	198
6.7	Effect of Trihoney and 1% Cholesterol Diet on Serum Homocysteine at Week 12	200
7.1	Effect of Trihoney and 1% Cholesterol Diet on Relative Liver Weight (%)	222
7.2	Baseline Liver Function Test	235
7.3	Liver Function Test at Week 12	236
7.4	Correlations (<i>r</i>) Between Serum Level of Liver Biochemical Parameters, Relative Liver Weight and Lipid Profile at Week 12	237
7.5	Effect of Trihoney on Insulin Resistance in Non-Alcoholic Fatty Liver Disease at Week 12	238
7.6	Effect of Trihoney on Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in Liver Homogenate of Non-Alcoholic Fatty Liver Disease (NAFLD) at Week 12	240

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Distribution of NCDs Globally by Cause of Death for both Sexes	12
2.2	Pathogenesis of Atherosclerotic Lesion Involves Hypercholesterolemia Induced Oxidative Stress, Inflammation and Immune Mechanisms	33
2.3	Trihoney	81
3.1	Coconut Oil (A), Cholesterol Emulsion (B)	92
3.2	Animal Housing (A). Animal Treatment (B). Animal Sacrificing (C)	98
3.3	Flow of the Experiment	99
3.4	Flow of Aortic and Liver Tissue Homogenate Preparation	103
3.5	The ELISA Procedure for Determination of Serum MDA	104
3.6	The ELISA Procedure for Determination of Tissue Homogenate MDA	105
4.1	The ELISA Procedure for Determination of Serum IL-1 β	114
4.2	The ELISA Procedure for Determination of Serum IL-6 and TNF- α	115
4.3	Follow Up of Animal's Food Intake and Body Weight During the Experiment	118
4.4	The Effects of Trihoney on Cardiovascular Risk Ratio (TC/HDL)	122
5.1	Assay Protocol for Superoxide Dismutase Enzyme Activity in Serum and in Tissue Homogenate	142
5.2	Assay Protocol for Glutathione Peroxidase Activity in Serum and in Tissue Homogenate	143
5.3	The ELISA Procedure for Determination of Serum Ox-LDL	145
5.4	Effects of Trihoney on Activities of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in the Serum at Week 12	147
5.5	Effects of Trihoney on Activity of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in Aortic Homogenate at Week 12	149
5.6	Effects of Trihoney and 1% Cholesterol Diet on Serum Oxidised Low-Density Lipoprotein (Ox-LDL) at Week 12	150

6.1	The ELISA Procedure for Determination of Serum ICAM-1 (CD54)	169
6.2	The ELISA Procedure for Determination of Serum VCAM-1	170
6.3	The ELISA Procedure for Determination of Serum Homocysteine Concentration	171
6.4	Comparison of Percentage of Atherosclerotic Aortic Lesions	172
6.5	Effect of Trihoney on Quantity of Atherosclerotic Plaques	173
6.6	Photomicrograph of Entire Cross Section of Aorta	178
6.7	Photomicrograph of Aorta Histology from Control Group (C)	179
6.8	Photomicrograph of Aorta Histology from Control Group Received Trihoney (C+H)	179
6.9	Photomicrograph of Aorta Histology from High Cholesterol Diet (HCD) Group Received 1% Cholesterol Diet	180
6.10	Photomicrograph of Aorta Histology from Atherogenic Group Received 0.3g/kg/day Trihoney (HCD+H ₁)	180
6.11	Photomicrograph of Aorta Histology from Atherogenic Group Received 0.6g/kg/day Trihoney (HCD+H ₂)	181
6.12	Photomicrograph of Aorta Histology from Atherogenic Group Received 2mg/kg/day Atorvastatin (HCD+At)	181
6.13	Photomicrograph of Aorta Histology from Control Group (C)	184
6.14	Photomicrograph of Aorta Histology from Control Group Received Trihoney (C+H)	184
6.15	Photomicrograph of Atheroma Histology from High Cholesterol Diet (HCD) Group Received 1% Cholesterol Diet	185
6.16	Photomicrograph of Atheroma Histology from Atherogenic Group Received 0.3g/kg/day Trihoney (HCD+H ₁)	185
6.17	Photomicrograph of Atheroma Histology from Atherogenic Group Received 0.6g/kg/day Trihoney (HCD+H ₂)	186
6.18	Photomicrograph of Atheroma Histology from Atherogenic Group Received 2mg/kg/day Atorvastatin (HCD+At)	186
6.19	Photomicrograph of Whole Aorta Sections	188
6.20	Photomicrograph of Aorta Histology from Control Group (C)	190

6.21	Photomicrograph of Aorta Histology from High Cholesterol Diet (HCD) Group Received 1% Cholesterol Diet	191
6.2	Photomicrograph of Aorta Histology from Atherogenic Treatment Group Received Trihoney 0.3/kg/day (HCD+H ₁)	192
6.23	Photomicrograph of Aorta Histology from Atherogenic Treatment Group Received Trihoney 0.6/kg/day (HCD+H ₂)	193
6.24	Photomicrograph of Aorta Histology from Atherogenic Treatment Group Received Atorvastatin 2mg/kg/day (HCD+At)	194
6.25	Effect of Trihoney and 1% Cholesterol Diet on Serum Intercellular Adhesion Molecule-1 (ICAM-1) at Week 12	195
6.26	Effect of Trihoney and 1% Cholesterol Diet on Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) at Week 12	197
7.1	Macromorphological and Cut Surface of Liver	223
7.2	Macromorphological and Cut Surface of Liver	224
7.3	Photomicrograph of Liver Histology from Control Group (C)	227
7.4	Photomicrograph of Liver Histology from Control Group Received 0.6g/kg/day Trihoney (C+H)	228
7.5	Photomicrograph of Liver Histology from Atherogenic Group Received 1% Cholesterol Diet (HCD)	229
7.6	Photomicrograph of Liver Histology from Atherogenic Group Received 0.3g/kg/day Trihoney (HCD+H ₁)	230
7.7	Photomicrograph of Liver Histology from Atherogenic Group Received 0.6g/kg/day Trihoney (HCD+H ₂)	231
7.8	Photomicrograph of Liver Histology from Atherogenic Group Received 2mg/kg/day Atorvastatin (HCD+At)	232
7.9	Effect of Trihoney on Lipid Peroxidation (Malondialdehyde-MDA) in Liver Homogenate of Non-Alcoholic Fatty Liver Disease at Week 12	241
8.1	Postulated Protective Mechanistic Pathways of Trihoney Against Atherosclerosis and NAFLD	263

LIST OF ABBREVIATIONS

AACE	American Association of Clinical Endocrinologists
ABC	ATP-binding cassette
ACC	American College of Cardiology
ACS	Acute coronary syndrome
AHA	American heart association
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
ASCVDs	Atherosclerotic cardiovascular diseases
AST	Aspartate aminotransferase
ATP	Adenosine triphosphate
BMI	Body mass index
CAT	Catalase
CBB	Coomassie Brilliant Blue
CCl ₄	Carbon tetrachloride
Cd	Cadmium
CETP	Cholesteryl ester transfer protein
CHD	Coronary heart disease
CHF	Congestive heart failure
cm	Centimetre
COX-1	Cyclooxygenase -1
COX-2	Cyclooxygenase -2
CRP	C-Reactive protein
CSF	Colony-stimulating factor
CVDs	Cardiovascular diseases
DALY	Disability-adjusted life year loss
DASH	Dietary advice to stop hypertension
DNA	Deoxyribonucleic acid
DNL	De novo lipogenesis
DNS	Department of nutrition sciences
DPX	Distyrene Plasticizer Xylene
EF	Extra cellular fat
EL	External elastic lamina
EMA	European medicines agency
EPCs	Endothelial progenitor cells
ER	Endoplasmic reticulum
FAO	Food and agriculture organization
FDA	Food and drug administration
FFA	Free fatty acids
FM	Foamy macrophage
FSH	Follicle stimulating hormone
FSMCs	Foamy smooth muscle cells
g	Gram
GGT	Gamma-glutamyl transferase
GIT	Gastrointestinal tract
GNI	General national income

GPx	Glutathione peroxidase
H&E	Haematoxylin and eosin
H ₂ O ₂	Hydrogen peroxide
HDL-c	High density lipoprotein cholesterol
HOMA-IR	Homeostatic model assessment of insulin resistance
HRP	Horseradish peroxidase
hs-CRP	High-sensitivity C reactive protein
ICAM-1	Intercellular adhesion molecule-1
IDL	Intermediate low-density lipoprotein
IHD	Ischaemic heart disease
IUM	International Islamic University Malaysia
IL-1 β	Interleukin-1beta
IL-6	Interleukin-6
Kcal	Kilocalorie
kg	Kilogram
L	Litre
LDL-c	Low-density lipoprotein cholesterol
LDL-R	Low-density lipoprotein receptor
LFT	Liver function test
LH	Luteinizing hormone
LOX-1	Lectin-like oxidized low-density lipoprotein receptor-1
LPC	Lysophosphatidylcholine
LXR α	Liver X receptors
M	Mean
MDA	Malondialdehyde
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MDR TB	Multidrug resistance tuberculosis
mg	Milligram
mL	Millilitre
μ L	Microliter
μ m	Micrometre
mm	Millimetre
mmol	Millimole
μ mol	Micromole
MMP-1	Metalloproteinase-1
MMP-9	Metalloproteinase-9
MNC	Mononuclear cell
mRNA	Messenger ribonucleic acid
MRSA	Methicillin-resistant <i>S. aureus</i>
MT	Masson's trichrome
mU	Milliunit
NADPH	Nicotinamide adenine dinucleotide phosphate
NAFLD	Non-alcoholic fatty liver disease
NASH	Non-alcoholic steatohepatitis
NBF	Neutral buffer formalin
NCCFN	National coordinating committee on food and nutrition Malaysia
NCDs	Noncommunicable diseases
NCEP	National Cholesterol Education Program

NF- κ B	Nuclear factor kappa B
NLRP3	Nod-like receptor protein 3
NO	Nitric oxide
NZW	New Zealand white rabbits
O ₂ ⁻	Superoxide anion
OD	Optical density
ONOO ⁻	Peroxynitrite
Ox-LDL	Oxidised low-density lipoprotein
PBS	Phosphate-buffered saline
PBUH	Peace and blessings upon him
PDGF	Platelets derived growth factor
PKC	Phosphate kinase C
PPAR- α	Peroxisome proliferator-activated receptor-alpha
PCSK-9	Proprotein convertase subtilisin/kexin type-9
RDI	Recommended daily intake
RM	Ringgit Malaysia
ROS	Reactive oxygen species
RSM	Response Surface Methodology
sdLDL	Small-density low-density lipoprotein
siRNA	Small interfering RNA molecules
SMCs	Smooth muscle cells
SOD	Superoxide dismutase
SR	Scavenger receptor
SREBP1c	Sterol regulatory element-binding protein 1c
SREBP2	Sterol regulatory element-binding protein 2
TA	Tunica adventitia
T. Bil	Total bilirubin
TC	Total cholesterol
TC/HDL	Cardiovascular risk ratio
TG	Triglycerides
TGF- β	Transforming growth factor-beta
TI	Tunica intima
TIA	Transient ischemic attack
TM	Tunica media
TMAO	Trimethylamine N-oxide
TNF- α	Tumour necrosis factor-alpha
TPC	Total phenolic content
TXNIP	Thioredoxin-interacting protein
U	Unit
UN	United nations
US	United states
US FDA	United States food and drug administration
VCAM-1	Vascular cell adhesion molecule-1
VLDL	Very-low density lipoprotein
WHO	World health organization

LIST OF SYMBOLS

-	Hyphen-minus
+	Plus sign
=	Equal sign
%	Percent sign
&	Ampersand
(Left parenthesis
)	Right parenthesis
,	Comma
.	Full stop
/	Solidus
:	Colon
;	Semicolon
[Left square bracket
]	Right square bracket
<	Less-than sign
>	Greater-than sign
≥	Equal to or greater- than sign
±	Plus-minus sign
°	Degree sign